Identification
- Summary
Uridine is a drug used to manage neuropsychiatric deficits associated with cerebrovascular diseases in combination with cytidine.
- Generic Name
- Uridine
- DrugBank Accession Number
- DB02745
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Uridine (DB02745)
- Weight
- Average: 244.2014
Monoisotopic: 244.069536126 - Chemical Formula
- C9H12N2O6
- Synonyms
- Uridina
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Neurologic deficits Combination Product in combination with: Cytidine (DB02097) •••••••••••• •••••••••• ••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UU6 snRNA-associated Sm-like protein LSm6 Not Available Humans UNucleoside-specific channel-forming protein tsx Not Available Escherichia coli (strain K12) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Pyrimidine Metabolism Metabolic MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy) Disease beta-Ureidopropionase Deficiency Disease Dihydropyrimidinase Deficiency Disease UMP Synthase Deficiency (Orotic Aciduria) Disease - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image CENTRUM Uridine (150 MG) + Cytidine (150 MG) Solution Oral Polifarma S.P.A. 2014-07-08 Not applicable Italy 
CENTRUM Uridine (150 mg) + Cytidine (150 mg) Injection Intramuscular; Intravenous Polifarma S.P.A. 2014-07-08 2016-06-12 Italy CENTRUM Uridine (150 MG) + Cytidine (150 MG) Injection, powder, for solution Intramuscular; Intravenous Polifarma S.P.A. 2014-07-08 Not applicable Italy CENTRUM Uridine (100 mg) + Cytidine (100 mg) Tablet Oral Polifarma S.P.A. 2014-07-08 2016-06-12 Italy CENTRUM Uridine (100 MG) + Cytidine (100 MG) Tablet Oral Polifarma S.P.A. 2014-07-08 Not applicable Italy
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrimidine nucleosides. These are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- Pyrimidine nucleosides
- Sub Class
- Not Available
- Direct Parent
- Pyrimidine nucleosides
- Alternative Parents
- Glycosylamines / Pentoses / Pyrimidones / Hydropyrimidines / Tetrahydrofurans / Heteroaromatic compounds / Vinylogous amides / Ureas / Lactams / Secondary alcohols show 7 more
- Substituents
- Alcohol / Aromatic heteromonocyclic compound / Azacycle / Glycosyl compound / Heteroaromatic compound / Hydrocarbon derivative / Hydropyrimidine / Lactam / Monosaccharide / N-glycosyl compound show 17 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- uridines (CHEBI:16704) / Ribonucleosides (C00299)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WHI7HQ7H85
- CAS number
- 58-96-8
- InChI Key
- DRTQHJPVMGBUCF-XVFCMESISA-N
- InChI
- InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1
- IUPAC Name
- 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
- SMILES
- OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O
References
- Synthesis Reference
Hidetoshi Yoshioka, Eiji Kojima, Shuji Ishida, Hiroyuki Yoshioka, Kunichika Murakami, "2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them." U.S. Patent US4954485, issued June, 1970.
US4954485- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000296
- KEGG Compound
- C00299
- PubChem Compound
- 6029
- PubChem Substance
- 46507015
- ChemSpider
- 5807
- BindingDB
- 50088517
- 11017
- ChEBI
- 16704
- ChEMBL
- CHEMBL100259
- ZINC
- ZINC000002583633
- Therapeutic Targets Database
- DNC001491
- PharmGKB
- PA130230921
- PDBe Ligand
- URI
- Wikipedia
- Uridine
- PDB Entries
- 1i5l / 1lnx / 1loj / 1tlz / 2fr6 / 2hwu / 2v0l / 3ivd / 3tij / 4eg2 … show 25 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Suicidal Thoughts 1 3 Completed Treatment Hereditary Orotic Aciduria 1 2 Completed Treatment 5'-Nucleotidase Syndrome 1 2 Completed Treatment Bipolar Disorder (BD) 1 2 Completed Treatment Depression, Bipolar 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular; Intravenous Injection, powder, for solution Intramuscular; Intravenous Solution Oral Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 165 °C PhysProp logP -1.98 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 135.0 mg/mL ALOGPS logP -1.8 ALOGPS logP -2.4 Chemaxon logS -0.26 ALOGPS pKa (Strongest Acidic) 9.7 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 119.33 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 52.57 m3·mol-1 Chemaxon Polarizability 21.81 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.8393 Blood Brain Barrier + 0.7679 Caco-2 permeable - 0.9175 P-glycoprotein substrate Non-substrate 0.7892 P-glycoprotein inhibitor I Non-inhibitor 0.9424 P-glycoprotein inhibitor II Non-inhibitor 0.9027 Renal organic cation transporter Non-inhibitor 0.9446 CYP450 2C9 substrate Non-substrate 0.7272 CYP450 2D6 substrate Non-substrate 0.8801 CYP450 3A4 substrate Non-substrate 0.6225 CYP450 1A2 substrate Non-inhibitor 0.9301 CYP450 2C9 inhibitor Non-inhibitor 0.9626 CYP450 2D6 inhibitor Non-inhibitor 0.9381 CYP450 2C19 inhibitor Non-inhibitor 0.9462 CYP450 3A4 inhibitor Non-inhibitor 0.9617 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9781 Ames test Non AMES toxic 0.7868 Carcinogenicity Non-carcinogens 0.9124 Biodegradation Ready biodegradable 0.6831 Rat acute toxicity 1.6859 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9648 hERG inhibition (predictor II) Non-inhibitor 0.8724
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 162.1483971 predictedDarkChem Lite v0.1.0 [M-H]- 162.0889971 predictedDarkChem Lite v0.1.0 [M-H]- 154.5408 predictedDeepCCS 1.0 (2019) [M-H]- 162.1483971 predictedDarkChem Lite v0.1.0 [M-H]- 162.0889971 predictedDarkChem Lite v0.1.0 [M-H]- 154.5408 predictedDeepCCS 1.0 (2019) [M+H]+ 166.2140971 predictedDarkChem Lite v0.1.0 [M+H]+ 163.4639971 predictedDarkChem Lite v0.1.0 [M+H]+ 156.9369 predictedDeepCCS 1.0 (2019) [M+H]+ 166.2140971 predictedDarkChem Lite v0.1.0 [M+H]+ 163.4639971 predictedDarkChem Lite v0.1.0 [M+H]+ 156.9369 predictedDeepCCS 1.0 (2019) [M+Na]+ 162.6416971 predictedDarkChem Lite v0.1.0 [M+Na]+ 162.1919971 predictedDarkChem Lite v0.1.0 [M+Na]+ 162.84947 predictedDeepCCS 1.0 (2019) [M+Na]+ 162.6416971 predictedDarkChem Lite v0.1.0 [M+Na]+ 162.1919971 predictedDarkChem Lite v0.1.0 [M+Na]+ 162.84947 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Poly(a) rna binding
- Specific Function
- Component of LSm protein complexes, which are involved in RNA processing and may function in a chaperone-like manner, facilitating the efficient association of RNA processing factors with their sub...
- Gene Name
- LSM6
- Uniprot ID
- P62312
- Uniprot Name
- U6 snRNA-associated Sm-like protein LSm6
- Molecular Weight
- 9127.525 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Nucleoside-specific channel forming porin activity
- Specific Function
- Constitutes the receptor for colicin K and phage T6, and functions as substrate-specific channel for nucleosides and deoxynucleosides.
- Gene Name
- tsx
- Uniprot ID
- P0A927
- Uniprot Name
- Nucleoside-specific channel-forming protein tsx
- Molecular Weight
- 33588.835 Da
References
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Nucleoside transmembrane transporter activity
- Specific Function
- Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR...
- Gene Name
- SLC29A1
- Uniprot ID
- Q99808
- Uniprot Name
- Equilibrative nucleoside transporter 1
- Molecular Weight
- 50218.805 Da
References
- Marce S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, Colomer D: Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica. 2006 Jul;91(7):895-902. [Article]
Drug created at June 13, 2005 13:24 / Updated at May 07, 2021 21:06